Please visit our MS learning channel on YouTube, which provides hundreds of MS related topics from many of our video recorded education programs and archived here: -- Be empowered with MS views and news. Opt-in with us:

~~ Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.


Tuesday, June 2, 2015

Effects of cannabis on cognitive function in patients with multiple sclerosis



While neuropsychological deficits have been reported in healthy individuals who use street cannabis, data in patients with multiple sclerosis (MS) are lacking. Given that MS is associated with cognitive deterioration, the aim of this study was to determine the neuropsychological effects of cannabis use in this population.


Two groups, each of 25 patients with MS (cannabis users and nonusers), were administered the Minimal Assessment of Cognitive Function in MS battery of neuropsychological tests, the Hospital Anxiety and Depression Scale (HADS), and the Structured Clinical Interview for the DSM-IV Axis I Disorders (SCID-I). Group-matching and regression analysis were used to control for the effects of age, sex, education, premorbid intelligence, disability, and disease course and duration on cognitive function.


Cannabis users performed significantly more poorly than nonusers on measures of information processing speed, working memory, executive functions, and visuospatial perception. They were also twice as likely as nonusers to be classified as globally cognitively impaired. There were no between-group differences on the HADS measures of depression and anxiety or lifetime SCID-I psychiatric diagnoses.


This cross-sectional study provides empirical evidence that prolonged use of inhaled or ingested street cannabis in patients with MS is associated with poorer performance on cognitive domains commonly affected in this population. Whatever subjective benefits patients may derive from using street cannabis (e.g., pain and spasticity relief) should be weighed against the associated cognitive side effects.

 Keep CURRENT with MS Views and NewsOPT-IN here


1 comment:

Cherie said...

If you drill down into this study more deeply, you will note that the "street cannabis" users were almost all not working, on disability, and had more impairment from their disease than the non-users. Also the non-users had an average of two years more of college level education than the users. The degree of long term pain, spasticity, sleep deprivation from same and severity of illness could just as easily contributed to some of the "deficits" as the use of the cannabis.

In similar studies funded by the NMSS, cognitive function was tested before and 45 minutes after "smoking a joint" and found to be impaired. I wonder if they have done similar response testing with Baclofen or Zanaflex 45 minutes after the dose is taken? My guess is the results would be similar.